Anavex Receives FDA Clearance for Blarcamesine Fragile X Trial

Key Facts

1Anavex Life Sciences received FDA clearance for its Investigational New Drug (IND) application for blarcamesine in Fragile X syndrome.

Anavex Life Sciences received FDA clearance for its Investigational New Drug (IND) application for blarcamesine in Fragile X syndrome. GlobeNewswire reported that the clearance enables the company to proceed with a Phase 2a clinical study in adult males with the condition, a genetic disorder that currently has no FDA-approved treatments.

AVXL closed at $1.49 on October 14, 2026, with the stock reaching a day high of $1.55 and a low of $1.45 during that session. The planned study aims to evaluate the safety, tolerability, and pharmacokinetics of blarcamesine oral solution, while including behavioral and cognitive measures as secondary endpoints.